Has Sophie Morse received payments from drug or device companies?

Yes. Drug and device makers reported $3,439 in general payments to Sophie Morse across 32 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sophie Morse did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sophie Morse come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sophie Morse

Hematology & Oncology · Summit, NJNPI 1184787723

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (52.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Exelixis Inc. at 35.6% of the total. Reporting peaked in 2021 at $2,037 and has fallen 99.2% since, to $17 in 2023. That places this record below the midpoint for hematology & oncology clinicians in NJ, where the typical reported total is $2,686.

$3,439in general payments, 2019–2025

Across 32 payments — averaging $107.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Exelixis Inc.$1K
Puma Biotechnology, Inc.$1K
AstraZeneca$694
GSK$100
Novartis$98
Lilly USA, LLC$53
plus $255 from 13 others

$188,190in research payments, 2019–2025

Across 12 payments — averaging $15,682 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$188K

What the payments were for

Consulting fees$1,79452%
Speaking & faculty fees$1,22536%
Food & beverage$42012%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Exelixis Inc.	1	$1,225
Puma Biotechnology, Inc.	2	$1,014
AstraZeneca	1	$694
GSK	1	$100
Novartis	5	$98
Lilly USA, LLC	4	$53
Eisai Inc.	2	$29
Merck	2	$28
Bristol Myers Squibb	2	$28
Pfizer	2	$28
Genentech USA, Inc.	2	$22
Pharmacyclics LLC, An Abbvie Company	1	$17
Ipsen Biopharmaceuticals, Inc	1	$16
Johnson & Johnson	1	$16
Daiichi Sankyo Inc.	1	$16
AbbVie	1	$15
Amgen	1	$14
E.r. Squibb & Sons, L.L.C.	1	$14
Gilead	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Cabometyx$1,225
Nerlynx$1,000

How this compares

$3,439 in reported general payments places this provider in the 50th percentile of 362 hematology & oncology providers in New Jersey.

See all hematology & oncology providers in New Jersey →

Other hematology & oncology in Summit

Bonni GuerinSummit$25K
Robert SpiegelWestfield$864K
Amit PatelJersey City$770K
Joshua StraussSpringfield$739K
Charles FarberMorristown$609K
Michael ScolaMorristown$506K
Eshan PatelSomerville$420K
Arturo Loaiza-BonillaPennington$406K
Ashish ShahSpringfield$394K
Carl HenningsonManasquan$349K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →